Colombia, Chile and Peru Wilson’s Disease Treatment Market, by Drugs (D-Penicillamine, Trientine, and Zinc Acetate), by Distribution Channel (Hospital Pharmacies and Government Distribution Channels), and by Country (Colombia, Chile, and Peru) is estimated to be valued at US$ 799.4 Thousand in 2022 and expected to exhibit a CAGR of 5.1% during the forecast period (2022-2030).

Key market players are focusing on gaining product approvals from regulatory bodies in order to expand their product portfolio, which is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market during the forecast period. For instance, in November 2020, Kadmon Holdings, Inc., a subsidiary of Sanofi S.A., announced that the U.S. Food and Drug Administration (FDA) has approved CLOVIQUE (Trientine Hydrochloride Capsules, USP), a room-temperature stable, branded generic product. Trientine hydrochloride is used for the treatment of Wilson's disease in patients who are intolerant of penicillamine.

Market players are also focused on inorganic growth strategies such as acquisition, which is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period. For instance, in April 2018, Alexion Pharmaceutical, Inc., a pharmaceutical company, announced that the company has signed the agreement to acquire Wilson Therapeutics AB, a biopharmaceutical company. WTX101 is the leading product of Wilson Therapeutics AB for the treatment of Wilson’s disease.

Colombia, Chile and Peru Wilson’s Disease Treatment Market - Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus (COVID-19) pandemic is expected to hamper the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period.

The COVID-19 outbreak was first reported in December 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 418.65 million cases and 5.8 million deaths due to coronavirus (COVID-19) were reported up till February 22, 2022, across the globe. The COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; 3) through its financial impact on companies and financial markets. Furthermore, in August 2020, there were 24,922 confirmed cases of COVID-19 among health workers in the public sector in Peru, representing 9.8% of public sector health resources for health (HRH) in the same month. In April 2021, the country reported 57,901 confirmed cases in the public sector HRH (PAHO/WHO, 2021), i.e. an increase of 22.48%, relative to the public-sector HRH data from December 2020.

Browse 39 Market Data Tables and 22 Figures spread through 175 Pages and in-depth TOC on Colombia, Chile and Peru Wilson’s Disease Treatment Market, by Drugs (D-Penicillamine, Trientine, and Zinc Acetate), by Distribution Channel (Hospital Pharmacies and Government Distribution Channels), and by Country (Colombia, Chile, and Peru).

To know the latest trends and insights prevalent in the Colombia, Chile and Peru Wilson’s disease treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/colombia-chile-and-peru-wilsons-disease-treatment-market-4959

Increasing healthcare expenditure by the government of Peru is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market. For instance, according to an article published by Knoema, a data technology company, in 2018, health expenditure per capita for Peru was US$ 369. Health expenditure per capita of Peru increased from US$ 116 US in 2004 to US$ 369 in 2018, growing at an average annual rate of 8.84%.

Key Takeaways of Colombia, Chile and Peru Wilson’s Disease Treatment Market:

  • Colombia, Chile and Peru Wilson’s disease treatment market is expected to exhibit a CAGR of 5.1% over the forecast period (2022-2030), owing to the rising number of approvals from regulatory bodies. For instance, in December 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to UX701 for the treatment of Wilson disease, a larger rare metabolic disease that affects more than 50,000 people in the developed world.
  • To address the unmet needs of Wilson’s disease treatment, market players are focused on research and clinical trials testing for new drugs. This contributes to the growth of Colombia, Chile and Peru Wilson’s disease treatment market. For instance, Vivet Therapeutics SAS, a biotechnology company, announced that the company has initiated a clinical trial for VTX-801 for the treatment of Wilson’s disease. The study is currently in phase 1. The trial was initiated in September 2021 and is expected to complete in July 2027.
  • Major players operating in Colombia, Chile and Peru Wilson’s disease treatment market include Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and Sanofi S.A.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo